A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma

Thalidomide monotherapy in relapsed/refractory multiple myeloma (MM) has a response rate of 30%. The combination of thalidomide with dexamethasone (Thal/Dex) is expected to improve responses, but it is unknown if the combination increases the rate of adverse events. Here, we conducted a systematic r...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: von Lilienfeld-Toal, Marie, Hahn-Ast, Corinna, Furkert, Kerstin, Hoffmann, Florian, Naumann, Ralph, Bargou, Ralf, Cook, Gordon, Glasmacher, Axel
Médium: Artigo
Jazyk:Inglês
Vydáno: Blackwell Publishing Ltd 2008
Témata:
Review Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2613233/
https://ncbi.nlm.nih.gov/pubmed/18637031
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1600-0609.2008.01121.x
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky